Yale Obesity Research Center (Y-Weight)

New Capabilities

Home institution of the trial's lead investigator

Eli Lilly's obesity drug retatrutide met its goals in two late-stage trials published in late September. The 12 mg dose produced 30.3% average weight loss over 104 weeks in adults with obesity, per Lilly's topline (the NEJM paper's primary 80-week endpoint was 25.0%), a level once seen mainly after bariatric surgery. In 1,152 adults with type 2 diabetes, the same dose cut weight 18.8% at 80 weeks, and 79% reached an HbA1c of 6.5% or lower.

Updated Oct 18